Hepatology International最新文献_第5页

Performance of the AASLD, EASL, and APASL Clinical Practice Guidelines in"grey zone"stages of Chinese patients with chronic hepatitis B. AASLD、EASL和APASL临床实践指南在中国慢性乙型肝炎患者“灰色地带”分期中的表现

IF 5.9 2区医学

Hepatology International Pub Date : 2025-05-14 DOI: 10.1007/s12072-025-10833-3

Hang-Yu Ma, Xue-Yan Yang, Yu-Xin Tian, Xi-Dong Li, Ying-Li He, Qiao Yang, Ming-Hua Zheng, Yu-Bao Zheng, Yue Yu, Ling-Yun Xu, Qian-Nan Wang, Tao Zhang, Yu Shi, Yu-Chen Fan

{"title":"Performance of the AASLD, EASL, and APASL Clinical Practice Guidelines in\"grey zone\"stages of Chinese patients with chronic hepatitis B.","authors":"Hang-Yu Ma, Xue-Yan Yang, Yu-Xin Tian, Xi-Dong Li, Ying-Li He, Qiao Yang, Ming-Hua Zheng, Yu-Bao Zheng, Yue Yu, Ling-Yun Xu, Qian-Nan Wang, Tao Zhang, Yu Shi, Yu-Chen Fan","doi":"10.1007/s12072-025-10833-3","DOIUrl":"10.1007/s12072-025-10833-3","url":null,"abstract":"Background/objective: Chronic hepatitis B (CHB) patients who do not meet any immunostaging criteria are categorized as the \"grey zone\" (GZ). However, there are discrepancies in the definition of the GZ in different areas.Aim: To investigate the prevalence and clinical characteristics of Chinese GZ patients and to validate the application value of three international guidelines.Methods: Data from 807 naïve CHB patients with liver biopsies from seven Chinese centres were retrospectively collected. GZ patients were defined and compared across four guidelines: the Chinese guidelines, the American Association for the Study of Liver Diseases (AASLD) guidelines, the European Association for the Study of the Liver (EASL) guidelines, and the Asian Pacific Association for the Study of the Liver (APASL) guidelines.Results: When the Chinese guidelines were used, 38.79% of patients were categorized into the GZ, 78.91% of whom were indicated for antiviral therapy. The EASL guidelines yielded a greater proportion of GZ patients (50.56%) than did the APSAL (36.68%) and AASLD guidelines (33.21%). The APASL guidelines yielded a lower proportion of GZ patients who were indicated for antiviral therapy (42.57%) than did the AASLD (47.76%) and EASL guidelines (60.54%). According to the AASLD, EASL, APASL and Chinese guidelines, if liver biopsy was not performed, 13.06%, 31.86%, 0% and 64.54% of GZ patients were indicated for antiviral therapy, respectively.Conclusions: GZ patients account for a significant proportion of CHB patients, with approximately half of them requiring antiviral therapy.Clinical trial registration: NCT06041022.","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Carvedilol and ascites prevention in decompensated cirrhosis: a hemodynamic advantage or selection bias? 卡维地洛预防失代偿期肝硬化腹水：血流动力学优势还是选择偏倚？

IF 5.9 2区医学

Hepatology International Pub Date : 2025-05-10 DOI: 10.1007/s12072-025-10843-1

Yadi Li, Zheng Wei, Jianlong Zhou

引用次数: 0

Unresolved heterogeneity in hepatic irAEs: critical limitations in prognostic interpretation for ICI-treated patients. 肝脏irae未解决的异质性：ici治疗患者预后解释的关键限制。

IF 5.9 2区医学

Hepatology International Pub Date : 2025-05-09 DOI: 10.1007/s12072-025-10842-2

Jiajie Lu, Li Huang

引用次数: 0

Midodrine plus propranolol: potential problems and controversies behind remarkable efficacy. Midodrine +心得安：疗效背后的潜在问题和争议。

IF 5.9 2区医学

Hepatology International Pub Date : 2025-05-04 DOI: 10.1007/s12072-025-10836-0

Zhenyu Shi, Shuxuan Wang, Yaqun Wang

引用次数: 0

Correction: The interplay between lymphatic system and portal hypertension: a comprehensive review. 纠正：淋巴系统和门静脉高压症之间的相互作用：一个全面的回顾。

IF 5.9 2区医学

Hepatology International Pub Date : 2025-05-02 DOI: 10.1007/s12072-025-10830-6

Pinky Juneja, Rajni Yadav, Dinesh M Tripathi, Savneet Kaur

引用次数: 0

Trends in the applications of artificial intelligence in fatty liver diseases. 人工智能在脂肪肝疾病中的应用趋势。

IF 5.9 2区医学

Hepatology International Pub Date : 2025-05-02 DOI: 10.1007/s12072-025-10827-1

Tian-Ao Xie, Li-Li Liufu, Hui-Jin Chen, Hao-Lin Chen, Xin-Ting Hou, Xuan-Rui Wang, Meng-Yi Han, Yu-Kai Shan, Rui-Jing Shen, Zhong-Yu Wu, Shi-Jie Li, Sarun Juengpanich, Win Topatana

{"title":"Trends in the applications of artificial intelligence in fatty liver diseases.","authors":"Tian-Ao Xie, Li-Li Liufu, Hui-Jin Chen, Hao-Lin Chen, Xin-Ting Hou, Xuan-Rui Wang, Meng-Yi Han, Yu-Kai Shan, Rui-Jing Shen, Zhong-Yu Wu, Shi-Jie Li, Sarun Juengpanich, Win Topatana","doi":"10.1007/s12072-025-10827-1","DOIUrl":"10.1007/s12072-025-10827-1","url":null,"abstract":"Introduction: Artificial intelligence (AI) has rapidly advanced and shows great potential in the prediction, diagnosis, treatment, and prognosis of fatty liver disease (FLD). This study aims to summarize AI's applications and emerging trends in FLD to inspire future research directions.Method: We analyzed 270 articles sourced from the Web of Science Core Collection published between 2006 and 2024. The study focuses on the medical application of AI in FLD, examining the contributions of authors, institutions, countries, keywords, and cited references.Results: AI is predominantly applied in FLD diagnosis, with progression from simple diagnostic tools to advanced methods for classifying FLD and assessing liver fat content. Moreover, the types of data used in AI development have evolved, incorporating a variety of new image and clinical data sources. AI is also being integrated into drug development and personalized nutritional therapies for FLD. Additionally, researchers are becoming increasingly interested in the application of AI to study FLD genes.Conclusion: We found that the applications of AI in FLD are mainly reflected in the prediction, diagnosis, therapy, and prognosis of FLD. In contrast to traditional medicine, AI has the potential to advance the fields of precision medicine and telemedicine, as well as to conserve additional social resources. Moreover, AI may help medical personnel from the perspective of traditional Chinese medicine, FLD prognosis, and the use of AI to analyze gene prediction and natural language processing (NLP).","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study. 急性肾损伤期1a增加肝硬化患者死亡率：一项前瞻性多中心队列研究

IF 5.9 2区医学

Hepatology International Pub Date : 2025-05-02 DOI: 10.1007/s12072-025-10837-z

Qin Shi, Jianpeng Li, Ke Wu

引用次数: 0

Plasma exchange improves survival with native liver in Wilson disease with new Wilson's index ≥ 11 & early hepatic encephalopathy. 血浆置换可提高新威尔逊氏指数≥11及早期肝性脑病威尔森氏病患者的生存。

IF 5.9 2区医学

Hepatology International Pub Date : 2025-05-02 DOI: 10.1007/s12072-025-10821-7

Snigdha Verma, Seema Alam, Bikrant Bihari Lal, Tamoghna Biswas, Vikrant Sood, Rajeev Khanna, Meenu Bajpai

{"title":"Plasma exchange improves survival with native liver in Wilson disease with new Wilson's index ≥ 11 & early hepatic encephalopathy.","authors":"Snigdha Verma, Seema Alam, Bikrant Bihari Lal, Tamoghna Biswas, Vikrant Sood, Rajeev Khanna, Meenu Bajpai","doi":"10.1007/s12072-025-10821-7","DOIUrl":"https://doi.org/10.1007/s12072-025-10821-7","url":null,"abstract":"Background and aim: Decision about liver transplant is difficult in Wilson disease (WD) with liver failure, especially with conflicting reports about new Wilson index (NWI). Therapeutic plasma exchange (TPE) can provide survival with native liver (SNL) in WD. This study was done to see the effect of TPE on outcome and identify factors for SNL.Methods: All cases of WD with liver failure (INR. ≥ 2.5) from prospectively maintained data were included for propensity score matching (PSM) to select TPE (n = 48) and no-TPE (n = 48) groups. Three sessions of TPE on three consecutive days were given to TPE group.Results: One hundred fifty-nine cases were included in the PSM with NWI & hepatic encephalopathy (HE) grading as predictors. SNL was comparable (26 vs. 17 cases (OR 1.45, p = 0.05) when the analysis was done in the whole cohort of 96 patients. SNL significantly improved when performed in those with no to early HE: TPE group (24/37) versus no-TPE group (14/34) (OR = 1.70, p = 0.03). Kaplan-Meier survival curves were significantly (log rank 0.019) improved in the TPE group when analyzing in no to early HE. Lower INR (adjusted OR 0.47, 95%CI 0.28-0.79, p = 0.005) and TPE administration (adjusted OR 3.12, 95%CI 1.10-9.4, p = 0.032) at enrollment were independently associated with SNL. Lower NWI (adjusted OR 0.686, 95%CI 0.53-0.89, p = 0.005) at 96 h was independently associated with SNL.Conclusions: TPE is independently associated with improvement in SNL by threefold in patients with NWI ≥ 11 and no to early HE. Patients with advanced HE should be offered immediate liver transplant. After 3 sessions of TPE, NWI < 11 increases SNL by 32%. Hence, NWI should be maintained below 11 with more sessions of TPE.","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lean-MAFLD: imperatives for updated evidence, mechanistic clarity, and methodological rigor. Lean-MAFLD：更新证据，机制清晰度和方法严谨性的必要性。

IF 5.9 2区医学

Hepatology International Pub Date : 2025-04-22 DOI: 10.1007/s12072-025-10832-4

Longshan Yang, Xiaojun Zeng

引用次数: 0

Revisiting the safety profile of tenofovir alafenamide: methodological reflections on real-world data. 重新审视替诺福韦的安全性概况：对真实世界数据的方法学反思。

IF 5.9 2区医学

Hepatology International Pub Date : 2025-04-21 DOI: 10.1007/s12072-025-10829-z

Mohamed El-Kassas, Khalid M AlNaamani

引用次数: 0